Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Expenses (2016 - 2026)

Intellia Therapeutics has reported Accumulated Expenses over the past 12 years, most recently at $9.3 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 77.15% to $9.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Mar 2026, down 77.15% year-over-year, with the annual reading at $49.9 million for FY2025, 107.11% up from the prior year.
  • Accumulated Expenses was $9.3 million for Q1 2026 at Intellia Therapeutics, down from $49.9 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $60.9 million in Q4 2022 and troughed at $9.3 million in Q1 2026.
  • The 5-year median for Accumulated Expenses is $40.8 million (2025), against an average of $35.3 million.
  • Year-over-year, Accumulated Expenses surged 301.99% in 2023 and then tumbled 77.15% in 2026.
  • A 5-year view of Accumulated Expenses shows it stood at $60.9 million in 2022, then plummeted by 56.28% to $26.6 million in 2023, then decreased by 9.54% to $24.1 million in 2024, then soared by 107.11% to $49.9 million in 2025, then tumbled by 81.3% to $9.3 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Accumulated Expenses are $9.3 million (Q1 2026), $49.9 million (Q4 2025), and $40.8 million (Q3 2025).